Evidence map›Paper›PMID 40695511›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2025

[Effects of

Lin-Xiao Teng, Qi An, Lei Wang, Nan Wang, Qing-Ling Kong, Rui Han, Yuan Wang, Lu Liu, Yan Wang, Shu-Mei Xu and 4 more

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lin-Xiao TengDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Qi AnDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Lei WangDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Nan WangDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Qing-Ling KongDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Rui HanDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Yuan WangDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Lu LiuDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Yan WangDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Shu-Mei XuDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Kun-Peng ShiDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Fang-Shan QiuDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Xi-Xi DUDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Jin-Rui ShiDepartment of Hematology and Oncology, Xuzhou Children's Hospital, Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the effects of methylenetetrahydrofolate reductase (

methodsChildren with ALL treated at the Xuzhou Children's Hospital of Xuzhou Medical University from January 2021 to April 2024 were selected for this study. Genotypes of

resultsIn the low-risk ALL group, the

conclusionsDetection of

Indexed as

Antimetabolites, Antineoplasticgamma-Glutamyl HydrolaseMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Polymorphism, GeneticPolymorphism, Single NucleotidePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleGenotypeHumansInfantMaleAntimetabolites, Antineoplasticgamma-Glutamyl HydrolaseMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)MTHFR protein, humanAcute lymphoblastic leukemiaChildMethotrexateMethylenetetrahydrofolate reductasePharmacogenomicsToxicity

Identifiers

PMID40695511
PMCPMC12291561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.